E
Enumera Molecular
A life science tools company developing rapid, low cost, liquid biopsy solutions
About Enumera Molecular
Enumera Molecular is a startup that operates in the healthcare technology sector, specifically in the field of clinical genomics. The company has developed a unique technology platform, EnumeraPlex™, which simplifies and reduces the cost of complex genomic testing. This platform is designed to democratize precision medicine by making it accessible to any lab, regardless of size or budget.
The company's primary offering is a streamlined workflow for conducting liquid biopsy and high-dimensional assays. These are types of tests used to detect and analyze genetic material, such as DNA or RNA, from a patient's blood sample. The traditional methods for these tests, such as whole genome sequencing, are often complex, time-consuming, and expensive. Enumera Molecular's technology simplifies these processes, making them faster and more cost-effective.
Enumera Molecular's target market includes any lab that conducts genomic testing, from small, independent labs to large, institutional labs. The company's business model is likely based on selling or licensing its technology platform to these labs. By reducing the operational costs and complexity of genomic testing, Enumera Molecular's technology could help labs increase their testing capacity and efficiency, potentially leading to increased revenue.
In conclusion, Enumera Molecular is a promising startup in the healthcare technology sector. Its innovative technology platform could revolutionize the field of genomic testing, making precision medicine more accessible and affordable.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2022
- Headquarters
- Scio Township, United States
- Employees
- 15
- Open positions
- None listed
- Dealroom signal
- 69.8/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Precision Medicine, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Sep 2022 | $19M | $76M | Undisclosed | ↗ |
| SERIES AEquity / VC | May 2022 | $13M | $50M | Arboretum Ventures | ↗ |
Growth signals
Latest recorded traffic for Enumera Molecular is 250 monthly website visits, down 50% over the last three months. Enumera Molecular's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Arboretum Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Enumera Molecular on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Enumera Molecular’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.